FY2025 EPS Estimates for Metsera Cut by Cantor Fitzgerald

Metsera, Inc. (NASDAQ:MTSR - Free Report) - Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Metsera in a note issued to investors on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings of ($3.58) per share for the year, down from their previous forecast of ($3.38). Cantor Fitzgerald currently has a "Overweight" rating on the stock.

A number of other brokerages also recently weighed in on MTSR. Evercore ISI started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an "outperform" rating for the company. Guggenheim began coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price objective for the company. Finally, Bank of America initiated coverage on Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price objective on the stock.

Metsera Stock Down 8.4 %

Shares of Metsera stock traded down $2.07 during trading on Monday, reaching $22.44. The company's stock had a trading volume of 698,023 shares, compared to its average volume of 669,347. Metsera has a one year low of $22.00 and a one year high of $32.81.

Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.